1. Home
  2. PPL vs RPRX Comparison

PPL vs RPRX Comparison

Compare PPL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PPL Corporation

PPL

PPL Corporation

SELL

Current Price

$35.50

Market Cap

25.4B

Sector

Utilities

ML Signal

SELL

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

SELL

Current Price

$68.52

Market Cap

28.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PPL
RPRX
Founded
1920
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.4B
28.4B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
PPL
RPRX
Price
$35.50
$68.52
Analyst Decision
Buy
Buy
Analyst Count
19
9
Target Price
$40.22
★ $72.00
AVG Volume (30 Days)
★ 7.9M
3.1M
Earning Date
11-06-2026
11-04-2026
Dividend Yield
★ 3.18%
1.37%
EPS Growth
★ 32.50
N/A
EPS
★ 1.59
1.03
Revenue
★ $9,042,000,000.00
$2,378,193,000.00
Revenue This Year
$6.89
$49.27
Revenue Next Year
$6.26
$9.11
P/E Ratio
★ $22.52
$66.52
Revenue Growth
★ 6.85
5.06
52 Week Low
$31.56
$37.31
52 Week High
$40.11
$70.37

Technical Indicators

Market Signals
Indicator
PPL
RPRX
Relative Strength Index (RSI) 54.18 65.56
Support Level $34.79 $55.48
Resistance Level $35.58 N/A
Average True Range (ATR) 0.55 1.58
MACD -0.07 -0.06
Stochastic Oscillator 36.56 65.28

Price Performance

Historical Comparison
PPL
RPRX

About PPL PPL Corporation

PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: